Gritstone is developing a second generation vaccine against SARS-CoV-2, the virus that causes COVID-19, with potential for both prolonged protection and potency, including against emerging Spike mutant forms of SARS-CoV-2.

Gritstone Oncology

Emeryville

Gritstone Oncology startup from Emeryville, United States is ranked null out of 2449 worldwide and null from the 748 startups in United States. See more information and additional rankings on the StartupBlink Global Ecosystem Map